Insulin-Like Growth Factor-1 (IGF-1)

Phase 2Small molecule

IIcahn School of Medicine at Mount Sinai

Insulin-Like Growth Factor-1 (IGF-1) is one of 5 small molecule programs targeting Phelan-McDermid syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Phelan-Mcdermid SyndromeActive, not recruiting

Phelan-Mcdermid SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Phelan-Mcdermid Syndrome

#DrugCompanyPhaseTrials

Pitocin

RRetrophin

Phase 2

1 2

Growth Hormone

Pfizer

Phase 2

1 3

Genotropin

EMD Serono

Phase 2

—4

NNZ-2591

NNeuren Pharmaceuticals Limited

Phase 3

3 5

Insulin-Like Growth Factor-1 (IGF-1)

IIcahn School of Medicine at Mount Sinai

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Phelan-McDermid syndrome1 trial

Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)

Completed·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT01525901·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Insulin-Like Growth Factor-1 (IGF-1). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Insulin-Like Growth Factor-1 (IGF-1) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Insulin-Like Growth Factor-1 (IGF-1). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Icahn School of Medicine at Mount Sinai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIcahn School of Medicine at Mount Sinai

Insulin-Like Growth Factor-1 (IGF-1)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Phelan-McDermid syndrome1 trial

References

Drug Info

Quick Facts

Related News